Daily non-political popular news in brief.
Experimental cancer pharmaceuticals under trial
10-23-2007 · EurekAlert!Advances in drug development have enabled scientists to attack new and unconventional cancer targets, leading to better treatments for cancer patients with fewer unwanted side effects. The following items highlight the early results from two experimental therapeutics, currently involved in Phase I or II trials, which are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Read more »
Keywords: experimental, cancer, pharmaceuticals, trial, pharmaceutical
« Previous | Next »
Similar news on "Experimental cancer pharmaceuticals under trial":
- Mass. General leading international trial of novel breast cancer drug
12-13-2006 · EurekAlert!
A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor.
Similar news · Read more »
- Study finds lapatinib shows promise as therapy for inflammatory breast cancer
12-14-2006 · EurekAlert!
In the first multi-center clinical trial conducted to better understand the complexities of a rare, aggressive and often lethal form of breast cancer, researchers have discovered that the experimental biological agent, lapatinib, successfully and specifically treats inflammatory breast cancer (IBC).
Similar news · Read more »
- Nexavar shown to significantly extend survival for patients with advanced liver cancer
02-12-2007 · EurekAlert!
Bayer Pharmaceuticals Corp., and Onyx Pharmaceuticals, Inc., today announced that an independent data monitoring committee (DMC) has reviewed the safety and efficacy data from the companies' pivotal Phase 3 trial in patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
Similar news · Read more »
- Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
01-10-2007 · EurekAlert!
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the New England Journal of Medicine has published their pivotal Phase III trial demonstrating that Nexavar (sorafenib) tablets doubled median progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), or kidney cancer.
Similar news · Read more »
- Herceptin does not increase heart failure in patients long-term
06-03-2007 · EurekAlert!
Risk of congestive heart failure in women treated with trastuzumab and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project trial B-31 led by the University of Pittsburgh School of Medicine. Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy.
Similar news · Read more »
- Scripps/UC San Diego scientists solve genome of promising marine organism
06-13-2007 · EurekAlert!
Scientists at UC San Diego's Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences have solved the genomic puzzle of an organism discovered in the oceans with potential for producing compounds showing promise in treating diseases such as cancer.
Similar news · Read more »
- Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
11-13-2007 · EurekAlert!
A sophisticated microscope that offers a "real-time" 3-D analysis of tissue samples might, in the future, reduce the number of needle biopsies traditionally needed from women suspected of having breast cancer, according to recent research published at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center.
Similar news · Read more »
- Anti-cancer drug damages brain vessels
02-11-2008 · EurekAlert!
New research may help explain why an anti-cancer drug causes potentially fatal brain inflammation in certain patients. Scientists at Harvard Medical School mimicked the drug's activity in mice and found that it damaged the cell lining that prevents fluid from leaking from the spinal cord into the brain. The results will be published online on Feb. 11 in the Journal of Experimental Medicine.
Similar news · Read more »
- Experimental procedure induces tolerance to mismatched kidney transplants
01-23-2008 · EurekAlert!
Four of five patients participating in a trial of an experimental protocol designed to induce immune tolerance to HLA-mismatched kidney transplants have been able to discontinue immunosuppressive drugs. The report in the Jan. 24 New England Journal of Medicine describes the first successful, intentional induction of tolerance across the HLA barrier in a group of transplant recipients.
Similar news · Read more »
- Synthetic production of potential pharmaceuticals dramatically simplified by Scripps research team
03-21-2007 · EurekAlert!
A team of researchers at The Scripps Research Institute has developed new techniques that dramatically reduce the time, complexity, and cost of synthesizing natural products with pharmaceutical potential. The work dislodges previously entrenched beliefs in the organic chemistry field about how such products must be produced, and could help to advance and expand the use of natural products in drug discovery programs
Similar news · Read more »
